Dossier
Dupixent
Coverage of Dupixent in the Nexus archive.
- Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul
Sanofi is discontinuing its eczema drug as part of a CEO-led pipeline overhaul, citing insufficient improvement over existing treatments like its own Dupixent.
- AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.